JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, open-label, phase Ib study to evaluate the safety, tolerability
and efficacy of JMT101 combined with afatinib in patients with advanced esophageal squamous
cell carcinoma who have failed standard treatment.